KRAS and cancer: In the 2L setting, median OS in patients with KRAS G12C–positive vs KRAS WT cancer treated with CIT alone was 11.3 (8.1–13.8) months vs 7.6 (6.3–9.3) months (aHR, 0.79; 95% CI, 0.61–1.03; p = 0.08).